HTG Molecular Diagnostics Company Profile (NASDAQ:HTGM)

About HTG Molecular Diagnostics (NASDAQ:HTGM)

HTG Molecular Diagnostics logoHTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Diagnostic & Testing Equipment
  • Sub-Industry: N/A
  • Symbol: NASDAQ:HTGM
  • CUSIP: N/A
  • Web: www.htgmolecular.com
Capitalization:
  • Market Cap: $21.06 million
  • Outstanding Shares: 11,448,000
Average Prices:
  • 50 Day Moving Avg: $1.87
  • 200 Day Moving Avg: $1.87
  • 52 Week Range: $1.20 - $4.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.07
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.5 million
  • Price / Sales: 3.83
  • Book Value: ($0.14) per share
  • Price / Book: -13.14
Profitability:
  • EBIDTA: ($20,910,000.00)
  • Net Margins: -432.74%
  • Return on Equity: -1,538.49%
  • Return on Assets: -131.17%
Debt:
  • Debt-to-Equity Ratio: -1.44%
  • Current Ratio: 1.58%
  • Quick Ratio: 1.46%
Misc:
  • Average Volume: 397,629 shs.
  • Beta: 0.61
  • Short Ratio: 4.82
 

Frequently Asked Questions for HTG Molecular Diagnostics (NASDAQ:HTGM)

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.60) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.60). The company had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.80 million. HTG Molecular Diagnostics had a negative net margin of 432.74% and a negative return on equity of 1,538.49%. View HTG Molecular Diagnostics' Earnings History.

When will HTG Molecular Diagnostics make its next earnings announcement?

HTG Molecular Diagnostics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for HTG Molecular Diagnostics.

Where is HTG Molecular Diagnostics' stock going? Where will HTG Molecular Diagnostics' stock price be in 2017?

3 brokerages have issued twelve-month price objectives for HTG Molecular Diagnostics' stock. Their predictions range from $6.00 to $6.50. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $6.17 in the next twelve months. View Analyst Ratings for HTG Molecular Diagnostics.

What are analysts saying about HTG Molecular Diagnostics stock?

Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:

  • 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (8/15/2017)
  • 2. HC Wainwright analysts commented, "We note that the launch of this new assay comes on schedule and expands the company’s existing menu following the launch of HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assays for research use. Investors may recall that this assay was designed for retrospective gene expression profiling (GEP) to complement traditional immunohistochemistry (IHC) testing, allowing investigators to assess mRNA expression of large numbers of biomarkers—up to 470 mRNA targets in this case—when formalin-fixed, paraffin-embedded (FFPE) sample availability is limited. Importantly, small and minimally invasive tissue biopsies are the trend nowadays in diagnostics, and within this setting, EdgeSeq PATH Assay allows for a more comprehensive profiling than conventional IHC. This may potentially lead to new GEP-based diagnostic or prognostic tests in oncology and beyond, in our view." (6/29/2017)

Who are some of HTG Molecular Diagnostics' key competitors?

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the folowing people:

  • Ann F. Hanham Ph.D., Independent Chairman of the Board
  • Timothy B. Johnson, President, Chief Executive Officer, Director
  • Shaun D. McMeans, Vice President of Finance and Administration, Chief Financial Officer
  • Patrick C. Roche Ph.D., Senior Vice President - Research and Product Development
  • Debra A. Gordon Ph.D. J.D., Vice President, Chief Legal Counsel and Secretary
  • John L. Lubniewski, Chief Business Officer
  • Donnie M. Hardison, Director
  • Harry A. George, Independent Director
  • James T. LaFrance, Independent Director
  • Lee Roy McCracken, Independent Director

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who owns HTG Molecular Diagnostics stock?

HTG Molecular Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NOVO HOLDINGS A (12.03%), NOVO HOLDINGS A (10.50%), GLAXOSMITHKLINE PLC (8.30%), GLAXOSMITHKLINE PLC (6.90%), FMR LLC (7.07%) and Vanguard Group Inc. (1.42%). Company insiders that own HTG Molecular Diagnostics stock include Debra A Gordon, Holdings A/S Novo, John L Lubniewski, Patrick C Roche, Plc Glaxosmithkline, Shaun D Mcmeans and Tim B Johnson. View Institutional Ownership Trends for HTG Molecular Diagnostics.

Who bought HTG Molecular Diagnostics stock? Who is buying HTG Molecular Diagnostics stock?

HTG Molecular Diagnostics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for HTG Molecular Diagnostics.

How do I buy HTG Molecular Diagnostics stock?

Shares of HTG Molecular Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTG Molecular Diagnostics stock can currently be purchased for approximately $1.84.


MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  169
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for HTG Molecular Diagnostics (NASDAQ:HTGM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $6.17 (235.14% upside)

Analysts' Ratings History for HTG Molecular Diagnostics (NASDAQ:HTGM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017HC WainwrightReiterated RatingBuy$6.00HighView Rating Details
5/16/2017Rodman & RenshawBoost Price TargetBuy -> Buy$4.50 -> $6.00HighView Rating Details
4/19/2017Canaccord GenuityBoost Price TargetHold$5.50 -> $6.50LowView Rating Details
3/28/2016Leerink SwannReiterated RatingOutperform$10.00 -> $5.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for HTG Molecular Diagnostics (NASDAQ:HTGM)
Earnings by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)
Earnings History by Quarter for HTG Molecular Diagnostics (NASDAQ HTGM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.53)N/AView Earnings Details
8/8/2017Q2($0.60)($0.60)$1.80 million$1.76 millionViewListenView Earnings Details
5/15/2017Q1($0.58)($0.73)$2.44 million$1.37 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.87)($0.92)$2.05 million$0.91 millionViewListenView Earnings Details
8/9/2016Q2($0.95)($0.98)$1.90 millionViewListenView Earnings Details
5/12/2016Q1($0.83)($1.02)$1.23 million$0.87 millionViewListenView Earnings Details
3/24/2016Q4($0.79)($0.83)$1.31 million$1.22 millionViewListenView Earnings Details
11/12/2015Q315($0.85)($0.76)$1.07 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.71)($1.73)$1.01 million$0.79 millionViewListenView Earnings Details
6/1/2015Q115($14.99)$1.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for HTG Molecular Diagnostics (NASDAQ:HTGM)
Current Year EPS Consensus Estimate: $-2.29 EPS
Next Year EPS Consensus Estimate: $-1.72 EPS

Dividends

Dividend History for HTG Molecular Diagnostics (NASDAQ:HTGM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for HTG Molecular Diagnostics (NASDAQ:HTGM)
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 21.67%
Insider Trades by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)
Institutional Ownership by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)
Insider Trades by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2017Holdings A/S NovoMajor ShareholderSell1,149,813$1.81$2,081,161.53View SEC Filing  
8/24/2017Holdings A/S NovoMajor ShareholderSell382,437$1.91$730,454.67View SEC Filing  
8/23/2017Holdings A/S NovoMajor ShareholderSell47,162$2.02$95,267.24View SEC Filing  
8/22/2017Holdings A/S NovoMajor ShareholderSell80,586$2.07$166,813.02View SEC Filing  
3/27/2017Plc GlaxosmithklineInsiderSell300,000$10.15$3,045,000.00View SEC Filing  
4/4/2016Debra A GordonVPSell1,672$2.89$4,832.08View SEC Filing  
4/4/2016John L LubniewskiInsiderSell796$2.89$2,300.44View SEC Filing  
4/4/2016Shaun D McmeansCFOSell1,601$2.89$4,626.89View SEC Filing  
4/4/2016Tim B JohnsonCEOSell4,914$2.89$14,201.46View SEC Filing  
3/14/2016Debra A GordonVPSell5,535$2.38$13,173.30View SEC Filing  
3/14/2016John L LubniewskiInsiderSell6,889$2.38$16,395.82View SEC Filing  
3/14/2016Patrick C RocheSVPSell5,929$2.38$14,111.02View SEC Filing  
3/14/2016Shaun D McmeansCFOSell5,651$2.38$13,449.38View SEC Filing  
3/14/2016Tim B JohnsonCEOSell10,621$2.38$25,277.98View SEC Filing  
3/9/2016Debra A GordonVPSell3,256$2.69$8,758.64View SEC Filing  
3/9/2016John L LubniewskiInsiderSell4,067$2.69$10,940.23View SEC Filing  
3/9/2016Patrick C RocheSVPSell3,491$2.69$9,390.79View SEC Filing  
3/9/2016Shaun D McmeansCFOSell3,325$2.69$8,944.25View SEC Filing  
3/9/2016Tim B JohnsonCEOSell6,299$2.69$16,944.31View SEC Filing  
8/24/2015Debra A GordonVPBuy1,000$5.16$5,160.00View SEC Filing  
8/18/2015Patrick C. RocheSVPBuy6,500$5.76$37,440.00View SEC Filing  
8/11/2015John L LubniewskiInsiderBuy5,000$7.67$38,350.00View SEC Filing  
5/11/2015A/S NovoMajor ShareholderBuy365,106$14.00$5,111,484.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for HTG Molecular Diagnostics (NASDAQ:HTGM)
Latest Headlines for HTG Molecular Diagnostics (NASDAQ:HTGM)
Source:
DateHeadline
finance.yahoo.com logoShould You Have HTG Molecular Diagnostics Inc’s (HTGM) In Your Portfolio?
finance.yahoo.com - September 23 at 9:36 AM
streetinsider.com logoHTG Molecular Diagnostics (HTGM) Says it Was Issued Two Method ... - StreetInsider.com
www.streetinsider.com - September 20 at 8:22 PM
finance.yahoo.com logoHTG Announces Issuance of Two Method Patents Related to its Technology
finance.yahoo.com - September 20 at 8:22 PM
streetinsider.com logoHTG Molecular Diagnostics (HTGM) Granted ISO 13485 Certification for Health Canada CMDCAS Requirements - StreetInsider.com
www.streetinsider.com - September 20 at 12:41 AM
streetinsider.com logoHTG Molecular Diagnostics (HTGM) Granted ISO 13485 Certification for Health Canada CMDCAS Requirements
www.streetinsider.com - September 19 at 7:40 PM
reuters.com logoBRIEF-HTG Molecular Diagnostics receives ISO 13485 certification for Health Canada CMDCAS requirements
www.reuters.com - September 18 at 7:07 PM
finance.yahoo.com logoHTG Molecular Diagnostics Receives ISO 13485 Certification for Health Canada CMDCAS Requirements
finance.yahoo.com - September 18 at 7:06 PM
americanbankingnews.com logoHTG Molecular Diagnostics' (HTGM) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - September 17 at 10:58 PM
benzinga.com logo22 Stocks Moving In Thursday's Pre-Market Session | Benzinga - Benzinga
www.benzinga.com - September 14 at 9:55 PM
globenewswire.com logoHTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay - GlobeNewswire (press release)
globenewswire.com - September 12 at 1:10 AM
finance.yahoo.com logoHTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay
finance.yahoo.com - September 11 at 8:07 PM
nasdaq.com logoHTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual Investment Conference - Nasdaq
www.nasdaq.com - September 7 at 12:37 AM
finance.yahoo.com logoHTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual Investment Conference
finance.yahoo.com - September 6 at 7:36 PM
americanbankingnews.com logoHTG Molecular Diagnostics, Inc. (HTGM) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - September 3 at 9:06 AM
finance.yahoo.com logoETFs with exposure to HTG Molecular Diagnostics, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 7:34 PM
americanbankingnews.com logoHTG Molecular Diagnostics, Inc. (HTGM) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - August 27 at 1:44 PM
finance.yahoo.com logoHTG Molecular Diagnostics, Inc. :HTGM-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 5:57 AM
americanbankingnews.com logoInsider Selling: HTG Molecular Diagnostics Inc (HTGM) Major Shareholder Sells 47,162 Shares of Stock
www.americanbankingnews.com - August 25 at 10:28 PM
americanbankingnews.com logoHoldings A/S Novo Sells 1,149,813 Shares of HTG Molecular Diagnostics Inc (HTGM) Stock
www.americanbankingnews.com - August 25 at 10:28 PM
americanbankingnews.com logoHoldings A/S Novo Sells 382,437 Shares of HTG Molecular Diagnostics Inc (HTGM) Stock
www.americanbankingnews.com - August 25 at 10:28 PM
americanbankingnews.com logoHTG Molecular Diagnostics, Inc. (HTGM) Major Shareholder Sells $166,813.02 in Stock
www.americanbankingnews.com - August 22 at 10:20 PM
americanbankingnews.com logoContrasting Varex Imaging (VREX) and HTG Molecular Diagnostics (HTGM)
www.americanbankingnews.com - August 21 at 10:22 PM
americanbankingnews.com logoHTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Short Interest Update
www.americanbankingnews.com - August 13 at 2:20 AM
americanbankingnews.com logoHTG Molecular Diagnostics, Inc. (HTGM) Lifted to Sell at ValuEngine
www.americanbankingnews.com - August 12 at 8:20 PM
americanbankingnews.com logoReviewing HTG Molecular Diagnostics (NASDAQ:HTGM) and VAREX IMAGING (VREX)
www.americanbankingnews.com - August 12 at 12:12 PM
globenewswire.com logoHTG Molecular Diagnostics' Technology to be Used in WIN Consortium NSCLC Clinical Trial - GlobeNewswire (press release)
globenewswire.com - August 9 at 7:53 PM
finance.yahoo.com logoHTG Molecular Diagnostics’ Technology to be Used in WIN Consortium NSCLC Clinical Trial
finance.yahoo.com - August 9 at 7:53 PM
finance.yahoo.com logoEdited Transcript of HTGM earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 7:53 PM
americanbankingnews.com logoHTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Announces Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - August 9 at 7:48 PM
seekingalpha.com logoHTG Molecular Diagnostics' (HTGM) CEO T. J. Johnson on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 12:18 AM
globenewswire.com logoHTG Molecular Diagnostics Reports Second Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 7:17 PM
finance.yahoo.com logoHTG Molecular Diagnostics Reports Second Quarter 2017 Results
finance.yahoo.com - August 8 at 7:17 PM
finance.yahoo.com logoETFs with exposure to HTG Molecular Diagnostics, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 12:45 AM
americanbankingnews.com logoHead to Head Survey: Cepheid (CPHD) and HTG Molecular Diagnostics (NASDAQ:HTGM)
www.americanbankingnews.com - July 31 at 9:33 AM
americanbankingnews.com logoHTG Molecular Diagnostics, Inc. (HTGM) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - July 30 at 1:30 PM
americanbankingnews.com logoHTG Molecular Diagnostics, Inc. (HTGM) Short Interest Up 46.3% in July
www.americanbankingnews.com - July 29 at 7:01 AM
streetinsider.com logoHTG Molecular Diagnostics (HTGM) Reports Second Companion Diagnostic Development Project with QIAGEN (QGEN)
www.streetinsider.com - July 29 at 3:40 AM
streetinsider.com logoHTG Molecular Diagnostics (HTGM) Reports Second Companion ... - StreetInsider.com
www.streetinsider.com - July 27 at 8:16 PM
finance.yahoo.com logoHTG Molecular Diagnostics Announces Second Companion Diagnostic Development Project with QIAGEN
finance.yahoo.com - July 27 at 8:16 PM
finance.yahoo.com logoHTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference
finance.yahoo.com - July 26 at 9:04 PM
nasdaq.com logoHTG Molecular Diagnostics to Hold 2017 Second Quarter Financial ... - Nasdaq
www.nasdaq.com - July 19 at 8:15 PM
globenewswire.com logoHTG Molecular Diagnostics to Hold 2017 Second Quarter Financial Results Conference Call on August 8, 2017 - GlobeNewswire (press release)
globenewswire.com - July 19 at 7:14 AM
seekingalpha.com logoHTG Molecular Diagnostics Has Its Own Niche
seekingalpha.com - July 18 at 9:56 PM
feeds.benzinga.com logoHTG Molecular Diagnostics to Hold 2017 Second Quarter Financial Results Conference Call on August 8, 2017
feeds.benzinga.com - July 18 at 4:34 PM
americanbankingnews.com logoHead-To-Head Review: WaferGen Bio-systems (WGBS) and HTG Molecular Diagnostics (NASDAQ:HTGM)
www.americanbankingnews.com - July 17 at 12:18 AM
americanbankingnews.com logoHTG Molecular Diagnostics, Inc. (HTGM) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - July 8 at 11:26 PM
nasdaq.com logoHTG Molecular Diagnostics Launches its HTG EdgeSeq PATH Assay - Nasdaq
www.nasdaq.com - June 30 at 7:45 PM
americanbankingnews.com logoHC Wainwright Reaffirms Buy Rating for HTG Molecular Diagnostics, Inc. (HTGM)
www.americanbankingnews.com - June 29 at 8:16 AM
globenewswire.com logoHTG Molecular Diagnostics Launches its HTG EdgeSeq PATH ... - GlobeNewswire (press release)
globenewswire.com - June 29 at 12:15 AM
reuters.com logoBRIEF-HTG Molecular Diagnostics has launched new HTG EdgeSeq PATH Assay
www.reuters.com - June 28 at 7:10 PM

Social

Chart

HTG Molecular Diagnostics (HTGM) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff